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nisms had a substantial impact on the results of health economic
evaluations.
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OBJECTIVES: Follicular non-Hodgkin’s lymphoma (FL) is the
most common indolent lymphoma occurring in the Western
Hemisphere with a variable clinical course. Because of high costs
of new treatments, we assessed direct health care costs associ-
ated with the most commonly prescribed treatments for FL.
METHODS: New and previously diagnosed FL patients (>18
years) known during 1997–1998 to 15 Dutch hospitals were ran-
domly selected for inclusion. Each patient was followed for three
years, from a distinct event in the disease course onwards, for
resource use associated with each of the treatments, including
‘watchful waiting’. The hospital perspective was adopted. Unit
costs were based on the 2003 price level. RESULTS: Two
hundred patients were included, of whom 75% percent under-
went >1 treatment during the 3-year data collection period (25%
was not treated because of a watchful waiting strategy (10%) or
complete remission (15%)). Allogeneic and autologous stem cell
transplantations were the most expensive treatments, with a
mean per patient cost of €45,326 (n = 7) and €18,866 (n = 9)
respectively (up to discharge only). This was followed by ﬂu-
darabine i.v. €10,651 (n = 33), rituximab (€10,628; n = 7), and
CHOP €7547 (n = 42). Classical FL treatments were found to
be the least expensive treatments used with an estimated cost for
CVP of €5268 (n = 58), for radiotherapy of €4218 (n = 52), and
for chlorambucil of €2476 (n = 53). CONCLUSIONS: This study
presents detailed information on resource use and costs associ-
ated with the most commonly prescribed FL treatments. In addi-
tion to differences in effectiveness, commonly used treatments
vary considerably in terms of resource use and overall cost. This
information is of value for resource planning.
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OBJECTIVES: To determine costs and identify cost drivers for
febrile neutropenia (FNE) in Belgium. METHODS: Direct costs
of FNE to health care payers were calculated from retro–pro-
jected chart review of patients treated during 2003 in 4 centres
(n = 93, 4 Hodgkin’s disease (HD), 36 Non–Hodgkin lymphoma
(NHL), 10 multiple myeloma, 35 breast cancer (BRCA) and 8
small–cell lung cancer). Clinical data and FNE related resource
utilization were collected from patient ﬁles. Cost data included
all FNE related costs. Resource use (including hospitalisation,
antimicrobials, perfusions, lab tests, interventions and other
drugs) was multiplied with unit costs from ofﬁcial sources.
Regression analysis to identify cost drivers was performed on
log–transformed costs using a mixed linear model. RESULTS:
The average number of FNE’s in patients with FNE was 1.3, the
ﬁrst FNE occurring after 1.7 cycles. The average number of
FNE’s tended to be higher in patients with hematological malig-
nancies and in patients receiving combination chemotherapy.
The mean cost per FNE episode, excluding G–CSF treatment and
secondary prevention, was €4221 (95% CI:3521–4921). Major
cost components were hospitalization (€2707), antimicrobial
therapy (€784) and tests (€636). Growth factors were prescribed
for FNE treatment and secondary prevention in 84% and 51%
of patients respectively. The average total cost of growth factors
was €2197. Mortality during chemotherapy was 11%. Regres-
sion analysis showed that underlying disease and survival were
independent cost drivers. NHL patients incurred 1.85 times
higher costs than others (95% CI:1.07–3.20, p = 0.0316).
Patients who died, either from FNE or from their underlying
disease, showed 1.52 times higher costs (95% CI:1.04–2.22, p =
0.0347) than survivors. Co–existence of thrombocytopenia or
anemia also signiﬁcantly predicted higher FNE costs. CON-
CLUSION: The cost of FNE varied according to underlying
disease. NHL patients showed the most elevated total FNE
related costs. These analyses of cost drivers enable to ﬁne–tune
data for economic analyses to relevant patient subgroup.
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OBJECTIVES: To estimate cost associated with informal care
giving in advanced stage Non-Small Cell Lung Cancer (NSCLC)
patients, identifying the costs drivers in Italy; to measure symp-
toms evolution using the LCS subscale of the FACT-L question-
naire. METHODS: A total of 104 patients (55 on second line
chemotherapy and 49 in supportive care) were enrolled in 18
Italian oncology departments and followed up for 3 months.
Main caregiver workload was assessed monthly by evaluating
the number of hours devoted to ten care giving tasks, presence
and activities of other informal or formal caregiver were regis-
tered, performance status was evaluated monthly by means of
the ECOG scale. Patients completed the LCS symptoms subscale
for each visit. Formal care giving time was valued according to
market prices; informal care giving hours were valued using the
wage rate for an equivalent service. The covariance analysis was
performed to check for inﬂuential factors in assistance need and
costs. RESULTS: During the 3-month observational period both
ECOG and LCS scores depreciated in the two groups. An equal
number of deaths were registered among patients in chemother-
apy and in supportive care. Monthly hours of informal care
giving increased from 124.37 to 166.9 for the chemotherapy
patients and from 141.92 to 150.97 for supportive care patients.
The whole home assistance cost accounted for €3159 for
chemotherapy and €4189 for supportive care patient. The regres-
sion analysis highlighted that symptom depreciation is a driver
of care giving time and costs and that the assistance cost
increases if the caregiver doesn’t live with the patient. CON-
CLUSIONS: The burden of assistance in NSCLC advanced
patients is mainly beard by family members who provide also
home health aide. As the population ages and family structure is
changing, social intervention targeted at unpaid family caregiver
will be needed to ease the economic, psychological and physical
burden of care giving.
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OBJECTIVES: To investigate the inﬂuence of the portion of
medical expense (30% of total amount of medical cost) paid
individually on physicians’ attitude toward treatment for the
patients with breast cancer in Japan. METHODS: A total of 165
physicians from board members of Japanese breast cancer
society (363 physicians) completed self-report questionnaires.
RESULTS: One hundred and forty-two out of 165 physicians
(87.7%) were surgeons, which reﬂected peculiar circumstance;
surgeons usually are involved in surgical treatment as well as
chemotherapy in Japan. Seventy-seven physicians (48%) had an
experience of having been asked by the patient for cheaper treat-
ment because of excessive individual payment. One hundred and
twenty physicians (74%) tried to select the treatment, giving
greater importance on the cost individually paid by the patients.
The difference between actual cost and the cost roughly esti-
mated by the physicians was the greatest in the treatment using
molecular targeting drugs (i.e. trastuzumab) and was smaller in
hormone therapy as well as conventional chemotherapy. The rate
of physicians unfamiliar with following national medical/welfare
system in Japan was “refunding from social assuror” (12%,
“interest free-loan by local government” (46%) and “tax reduc-
tion for medical expenses” (21%). The physicians supporting
expansion of the portion of the medical expense uncovered by
social insurance was three times greater than those negative for
it. CONCLUSION: 1) About 60 percent of breast cancer spe-
cialists had keen senses on an economical side of the treatment
especially on the portion of medical expense paid individually.
2) Excessive individual payment exerted an inﬂuence on contin-
uing effective chemotherapy.
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OBJECTIVES: Cutaneous cancer is a general term given to a
range of skin tumours. Its severity is determined by the size and
location of the primary tumour, and whether there are metas-
tases. This study was designed to obtain a clear understanding
of the current treatments and costs related to the clinical man-
agement of cutaneous cancer in Germany. This study was under-
taken to be able to contrast the efﬁcacy and health economic
beneﬁts of current care relative to emerging ablation technolo-
gies being developed. METHODS: A Care Map was developed
to capture how patients with cutaneous cancer are treated in
Germany from diagnosis through follow up. In this study, the
focus was on treatment of tumours not larger than 20cm2. Infor-
mation in the public domain was supplemented with informa-
tion gathered through expert interviews with six dermatologists.
RESULTS: After diagnosis of cutaneous cancer, patients were
mainly treated with Mohs surgery (32%), conventional surgery
(30%), chemotherapy (14%) and radiotherapy (12%). Other
treatments used include limb perfusion, phototherapy (e.g.
PUVA), laser therapy, immunotherapy or combinations of these
therapies. After ﬁrst line treatment, more than 85% of patients
are cleared of their cancer and are subsequently followed for
recurrence of the tumour. Recurrent tumours are mainly treated
with Mohs surgery (31%), conventional surgery (25%), or
chemotherapy (22%). Severe adverse events are rare. The total
average charge to the third party payer of ﬁrst-line treatment is
approximately €3540. For the second-line treatment the costs are
approximately €3756. CONCLUSIONS: Current treatment of
small cutaneous cancers varies depending upon the type of
tumour. Mohs surgery, conventional surgery, chemotherapy and
radiotherapy are the main treatment options. First line treatment
is very successful, with 85% of patients being cured. However,
the 15% of patients with recurrences will need to undergo a
second-line treatment, impacting the patient and health care
system.
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ECONOMIC ANALYSIS OF BISPHOSPHONATES FROM THE
PAYERS PERSPECTIVE IN BRAZIL
Calabró AA
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OBJECTIVES: To evaluate the incidence of skeletal-related
events (SREs) in cancer patients with bone metastasis, their incre-
mental direct costs and measure the potential economic value of
the use of bisphosphonates. METHODS: A retrospective analy-
sis of medical provider’s bills from 3.219 cancer patients (breast,
prostate, lung, renal, multiple myeloma) for 24 private health
care plans in Brazil was constructed and analyzed from the
private payers’ perspective. Patient population was divided into
two groups: placebo (2.431 patients with no use of bisphospho-
nate) and bisphosphonate (787 patients treated with Zometa®,
Aredia®, Ostac® or Bonefós®). The total health care utilization
cost per patient per year was calculated as the sum of the average
pharmaceutical cost (bisphosphonate cost plus the cost of infu-
sion, outpatient day hospital, materials and other prescription
drugs) and the average cost per patient in treating a SRE, con-
sidering the real incidence for each bisphosphonate. SREs were
deﬁned as pathological bone fracture, spinal cord compression,
radiation therapy to bone, and surgery to bone. RESULTS: The
incidence of clinical and surgical SREs was: Zometa® (15%;
1%), Aredia® (19%; 2%), Ostac®/Bonefós® (26%; 13%),
placebo (37%; 5%). The cost per patient in treating a clinical
SRE, in USD, ranged from $58 to $2744. The cost per patient
in treating a surgical SRE ranged from $610 to $21,250 (patient
who required surgery to bone). The average cost per patient in
treating a clinical SRE was $480 and in treating a surgical SRE
was $5445. The total health care utilization cost per patient per
year was the lowest for Zometa ($2106) followed by Aredia
($2375), Ostac/Bonefós ($2818) and placebo ($2637). CON-
CLUSION: Among the bisphosphonates analyzed, Zometa®
showed to be effective at preventing the skeletal-related events
with the lowest total health care utilization cost.
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PRACTICES
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OBJECTIVES: Signiﬁcant changes in Medicare reimbursement
for outpatient oncology services are included as part of the
Medicare Modernization Act of 2003. The objective of this study
was to identify the “true cost” associated with the drug-related
handling for the preparation and delivery of chemotherapy
doses. METHODS: Two academic medical outpatient infusion
centers (Universities of Utah and Wisconsin) and two commu-
nity cancer centers in the U.S. (Fairfax, Virginia and Mont-
gomery, Alabama) provided data used to estimate all “ﬁxed
costs” associated with the preparation of chemotherapy includ-
ing drug storage, space, insurance management, inventory and
waste management, pharmacy staff payroll, equipment, supplies,
information resources and shipping. These costs were annualized
and then divided by the number of chemotherapy doses given at
each site per year. A Time-and-Motion study was also performed
